ArticleScientific reports2024
Prevalence and associated risk factors of post COVID fatigue among Parkinson's disease patients during one year follow up.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
One of the most common post-COVID-19 condition is persistent fatigue, while post-COVID fatigue among Parkinson's disease (PD) patients is less known. This study was aimed to investigate the prevalence and risk factors of post-COVID fatigue in PD patients at 1 month and 12 months after symptom onset. PD patients attending clinic from December 2022 to January 2023 were enrolled consecutively in the study. All participants were assessed demographics, details of COVID-19 infection, clinical characteristics as well as fatigue status with Fatigue Severity Scale (FSS) (cutoff ≥ 36) at 1-month and 12-month after symptom onset. Univariate and multivariate Logistic regression analysis were used to evaluate the risk factors of post-COVID fatigue. Fatigue symptoms were reported by 75.89% of PD patients and associated with decreased physical activity and number of initial symptoms of COVID-19 at 1 month. Meanwhile, 32.99% of PD patients at 12 months reported persistent fatigue. Using of antiviral drugs, decreased physical activity, anxiety status and delayed ON were associated with persistent fatigue at 12 months. Clinically persistent fatigue was pervasive in our study at 12-month after COVID infection. These findings implicate using of antiviral drugs, decreased physical activity, anxiety status and delayed ON were possible predictors of post-COVID persistent fatigue.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.